Curriculum vitae

Samuli Ripatti, PhD, is the Director of the Institute for Molecular Medicine Finland (FIMM), HiLIFE,  Professor of Biometry at the Faculty of Medicine, University of Helsinki, and Affiliated Faculty Memberat Massachusetts General Hospital and Broad Institute of MIT and Harvard. He is chairing the Research Council Finland’s Centre of Excellence in Complex Disease Genetics and the EU H2020-funded Intervene Consortium. His research group studies genetic variation in the Finnish population and its effects on common complex disease risks and management. He is one of the pioneers in developing and testing the clinical translation of polygenic risk scores in disease prevention and early detection.

Dr Ripatti’s research focuses on cardiometabolic diseases and cancers as models to learn about new

disease mechanisms and to develop novel genome-based strategies for diagnosis, prevention and stratified treatment. He has played a central role in developing and testing the use of polygenic risk in prevention of cardiometabolic diseases and common cancers. He is also the PI of the GeneRISK Study, a pioneering longitudinal research project in studying the health impact of returning genetic and clinical risk for cardiovascular diseases to the study participants. He has published over 450 articles and book chapters.